Gilead's Biktarvy Patent Extended to 2036
Gilead Sciences settled lawsuits with generic manufacturers, securing market exclusivity for Biktarvy until April 2036.
Already have an account? Sign in.
Gilead Sciences settled lawsuits with generic manufacturers, securing market exclusivity for Biktarvy until April 2036.
Werewolf Therapeutics announces a 64% workforce reduction to save money, key executives leave with severance, and a new finance officer steps in as the company explores partnerships and funding options.
Disc Medicine's bitopertin gets turned down by FDA for treating EPP, a painful genetic condition making skin ultra-sensitive to sun.
ICE plans to spend $38.3 billion converting warehouses nationwide—including one near Hagerstown, MD—into large detention facilities for mass deportations. Companies like CoreCivic and GEO Group stand to benefit from the immigration detention boom.